Clinical Trial: Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma

This study is no longer recruiting patients.

Sponsors and Collaborators: National Cancer Institute (NCI)
Fred Hutchinson Cancer Research Center
Information provided by: National Cancer Institute (NCI)


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy, peripheral stem cell transplantation, and radiation therapy in treating patients with recurrent metastatic Ewing's sarcoma, peripheral primitive neuroectodermal tumor, or rhabdomyosarcoma.

Condition Treatment or Intervention Phase
recurrent childhood rhabdomyosarcoma
adult rhabdomyosarcoma
recurrent peripheral primitive neuroectodermal tumor
recurrent tumors of the Ewing's family
recurrent adult soft tissue sarcoma
 Drug: busulfan
 Drug: filgrastim
 Drug: melphalan
 Drug: thiotepa
Phase I

MedlinePlus related topics:  Bone Cancer;   Cancer;   Cancer Alternative Therapy;   Soft Tissue Sarcoma

Study Type: Interventional
Study Design: Treatment

Official Title: Phase I Study of Busulfan, Thiotepa, and Melphalan Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Transplantation and Followed by Total Marrow (Skeletal) Irradiation Followed by PBSC Rescue in Patients with High-Risk Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor or Rhabdomyosarcoma

Further Study Details: 

Study start: March 1998

OBJECTIVES: I. Estimate the maximum tolerated dose of total bone marrow irradiation (TMI) that can be administered as planned consolidation utilizing autologous peripheral blood stem cell support following local radiotherapy (if indicated) and prior busulfan, melphalan, and thiotepa. II. Examine the efficacy of this dual transplant approach for high-risk patients with Ewing's sarcoma, peripheral primitive neuroectodermal tumor, or rhabdomyosarcoma in first complete remission or greater.

PROTOCOL OUTLINE: This is a two part, radiation dose escalation study. Peripheral blood stem cells (PBSC) are collected after 5-6 daily injections of G-CSF. The PBSC are infused in two halves. One half is given after chemotherapy and the other half after total marrow irradiation (TMI). Transplant #1 (part one) consists of chemotherapy and PBSC infusion. Busulfan (BU) is administered orally every 6 hours for 3 days for a total of 12 doses on days -8, -7 and -6. Melphalan is intravenously infused over 30 minutes for 2 days on days -5 and -4. Thiotepa is intravenously infused over 2 hours on days -3 and -2. PBSC are infused on day 0, 36-48 hours after completion of chemotherapy. Patients are considered for local irradiation therapy between transplant #1 and #2 if tissue limiting irradiation doses to bulk tumor site have not previously been administered. The local irradiation is given immediately prior to TMI administration. Transplant #2 starts sometime between day 60 and 120 after transplant #1. For transplant #2, cohorts of 4 patients are treated with TMI twice a day for 5 days at initial dose level on days -5 through -1. TMI is administered over 30-40 minutes. The second half of the PBSC is infused 1-24 hours following the last dose of TMI. After treatment of at least 4 patients at the initial TMI dose level, dose levels escalate in the absence of toxicity. If there is no dose limiting toxicity (DLT) in the current group of 4 patients, the next cohort is treated at the next higher dose level. If 1 of the 4 patients experiences DLT, the next cohort is treated at the same dose. If 1 DLT is seen among 8 patients treated at a dose, then the next cohort is treated at the next higher dose level. If 2 patients out of 8 experience DLT, this dose is identified as the maximum tolerated dose (MTD). If 1 out of 4 or 3 out 8 patients experience DLT at a dose level, the next lower dose level is identified as the MTD. Each patient in a cohort is observed for a minimum of 28 days prior to escalation to the higher dose level. Tumor restaging occurs approximately 9 months after initial transplant, then at 12 months and annually thereafter.

PROJECTED ACCRUAL: An expected 12-16 patients are required to complete this study. Accrual should last 3-4 years at 4-5 patients per year.


Ages Eligible for Study:  up to  49 Years



--Disease Characteristics--

--Prior/Concurrent Therapy--

  • Biologic therapy: Not specified
  • Chemotherapy: See Disease Characteristics
  • Endocrine therapy: Not specified
  • Radiotherapy: No prior dose limiting irradiation to any organ site
  • Surgery: See Disease Characteristics

--Patient Characteristics--

  • Age: Under 50
  • Performance status: Karnofsky 70-100%
  • Life expectancy: Greater than 3 months
  • Hematopoietic: Granulocyte count at least 1,000/mm3; Platelet count at least 100,000/mm3
  • Hepatic: Bilirubin less than 2.0 mg/dL
  • Renal: Creatinine clearance greater than 50% of normal
  • Pulmonary: LVEF greater than 41%
  • Other: HIV negative; Not pregnant

Location Information

      Fred Hutchinson Cancer Research Center, Seattle,  Washington,  98109,  United States

Study chairs or principal investigators

Jean E. Sanders,  Study Chair,  Fred Hutchinson Cancer Research Center   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000065777; FHCRC-1205.00; NCI-G97-1331
Record last reviewed:  April 2004
Last Updated:  October 13, 2004
Record first received:  November 1, 1999 Identifier:  NCT00003081
Health Authority: United States: Federal Government processed this record on 2005-04-08

Cache Date: April 9, 2005